SAVE THE DATE FOR THE APPLIED PHARMACEUTICAL TOXICOLOGY (APT) 2024 CONFERENCE !
May 14-6, 2024 @ Merck Research Laboratories, Boston, MA
Download APT 2023 Program Guide
Plenary Speakers Confirmed for 2023
![]() |
Plenary Lecture Dennis O. Clegg, PhDWilcox Family Chair in Biomedicine, Co-Director, Center for Stem Cell Biology and Engineering Professor, Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara A Stem Cell-Derived Implant for Dry Age-related Macular Degeneration |
![]() |
Plenary Lecture Monicah Otieno, PhD Head of Toxicology @ Bill and Melinda Gates Medical Research Institute Safety Considerations for Selection and Development of Combination Therapies for Tuberculosis |
![]() |
Plenary Lecture Paul Roney, PhD, DABT Regulatory Specialist, Regulatory and Quality Affairs Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR) BARDA, Medical Countermeasure Development, and the Animal Rule |
||
Speakers Confirmed for 2023
![]() |
Rachel Andrews, PhD Principal Scientist-Pathologist, Safety Assessment @ Genentech Looking to the Future: Evolving Considerations for Intravitreal (Ocular) Biologics Combination Toxicity Studies |
![]() |
Joel Bercu, PhD Executive Director @ Gilead Sciences I've Got a Nitrosamine Impurity: What Now? |
![]() |
Helen Booler, BVetMed Director Project Pathology @ Novartis Ocular Inflammation in Non-clinical Ocular Toxicity Studies - An Evolution Understanding, Approaches, and Impact |
![]() |
Steven Cassar, MS Senior Scientist II Toxicology@ AbbVie Utility of Zebrafish for Detecting Mitochondrial and Biliary Toxicities in Preclinical Safety |
![]() |
Anuhar Chaturvedi, PhD Associate Director Non-Clinical Safety @ BioNTech SE Preclinical Safety Evaluation of mRNA Cancer Therapeutics: A Platform Approach |
![]() |
Kevin Cross, PhD Vice President @ Instem Nitrosamine SAR: I'll Show You a Read-across |
![]() |
Nora Denk, DVM Global Preclinical In Vivo Ophthalmology Expert @ Roche, Basel The Bigger Picture of Inflammation |
![]() |
Joel Federspiel, PhD Principal Scientist @ Pfizer Elucidating On and Off-target Effects of Protein Degraders Through Quantitative Proteomics |
![]() |
Craig Ferris, PhD Chief Scientific Officer @ Ekam Imaging In vivo Neuropathology: Detecting the Neurotoxicity of Candidate Drugs during Early Drug Discovery |
![]() |
Erika Fletcher, PhD Scientific Advisor & Co-founder @ IMMUNEED AB, Uppsala, Sweden ID.Flow: A Physiologically Relevant Test System for Nonclinical Safety Assessment of Different Drug Modalities |
![]() |
Kimberly Homan, PhD Director of the Complex In Vivo Systems Lab, Safety Assessment @ Genentech Leveraging Organoids and Organs-on-Chip in Drug Development |
![]() |
Vibha Jawa, PhD Executive Director @ BMS Preclinical Immunogenicity Risk Assessment Approaches for Traditional Biologics and Next Generation Novel Modalities |
![]() |
Robert Jolly, MPH, DABT Risk Assessment Toxicologist @ Eli Lilly Schrödinger's Cat is Dead, but Not from Nitrosamine Exposure...Probably |
![]() |
Ofer Levy, MD, PhD Director, Precision Vaccines Program @ Boston Children's Hospital Precision Vaccines: Bringing Precision Medicine to Vaccinology |
![]() |
Ian Nessler, PhD Senior Scientist @ AbbVie Engineering Antibody-Drug Conjugates for Solid Tumors |
![]() |
Diogo Rodrigues Ferreirinha, MSc European Senior Account Manager @ Charles River Laboratories Screening of Antibody, Protein, and Cell Therapeutics for Potential Off-targets Using Human Cell Microarray Technology |
![]() |
Melissa Schutten, DVM, PhD Senior Director, Head of Pathology @ Seagen Current Strategies of Lead Op for Existing and Novel Conjugates |
![]() |
Ruchi Srivastava, PhD Senior Scientist @ AbbVie Advancement in Translational In Vitro Models for Preclinical Immunogenicity and Immunosafety Risk Assessment |
![]() |
Yoav Timsit, PhD, DABT Director, Preclinical Safety @ Blueprint Medicines Current Strategies in Secondary Pharmacology and its Impact on the Safety of New Medicines |
![]() |
Renzong Xie, PhD, DABT VP of Toxicology Research Department @ Medicilon Nonclinical Safety Evaluation of Nanolipid Particles |
![]() |
Cuixian (Trisha) Yang, PhD Associate Principal Scientist @ Merck The Ultra-fast Journey of First Merck ADC |
|
Martin Stahl, PhD Senior Scientist, Research & Development & Danny Leung, BSc Contract Assay Services Human Intestinal Organoid Culture System for Drug-induced Gastrointestinal Toxicity Screening |
![]() |
Bruno Filippi, PhD Vice President, Liver Safety @ InSphero Liver Spheroid Models for Predictive and Investigative Toxicology |
|
Marcela Alomia, PhD Global Director of Sales for Preclinical Solutions @ DLS & Emer Clarke, PhD CSO @ ReachBio ReachBio Acquired by Discovery Life Sciences, Expanding Toxicology Solutions |
Sessions for the 2023 Discovery Toxicology Workshop
Session I: Alternative Models
Session II: Understanding Unwanted Pharmacology
Session III: In Vitro and In Silico Predictive Immunogenicity
Sessions for the 2023 Development Toxicology Workshop
Session IV: An Eye on the Eye!
Session V: ABC's of ADC's
Session VI: Nitrosamine Impurities